skip navigation links
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 14.12e (Release date: 2014-12-29-08:00)
SearchBox Top
SearchBox Bottom
CDK4/6 Inhibitor LEE011 (Code C95701)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: CDK4/6 Inhibitor LEE011

Definition: An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

Display Name: CDK4/6 Inhibitor LEE011

Label: CDK4/6 Inhibitor LEE011

NCI Thesaurus Code: C95701 (Search for linked caDSR metadata)

NCI Metathesaurus CUI: CL428167  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
CDK4/6 Inhibitor LEE011

External Source Codes: 
NCI META CUI CL428167 (see NCI Metathesaurus info)
PDQ Closed Trial Search ID 689330 (check for NCI PDQ closed clinical trial info)
PDQ Open Trial Search ID 689330 (check for NCI PDQ open clinical trial info)

Other Properties:
code C95701
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom